Literature DB >> 31823097

SUV variability in EARL-accredited conventional and digital PET.

Daniëlle Koopman1,2, Pieter L Jager3, Cornelis H Slump4, Siert Knollema3, Jorn A van Dalen5.   

Abstract

BACKGROUND: A high SUV-reproducibility is crucial when different PET scanners are in use. We evaluated the SUV variability in whole-body FDG-PET scans of patients with suspected or proven cancer using an EARL-accredited conventional and digital PET scanner. In a head-to-head comparison we studied images of 50 patients acquired on a conventional scanner (cPET, Ingenuity TF PET/CT, Philips) and compared them with images acquired on a digital scanner (dPET, Vereos PET/CT, Philips). The PET scanning order was randomised and EARL-compatible reconstructions were applied. We measured SUVmean, SUVpeak, SUVmax and lesion diameter in up to 5 FDG-positive lesions per patient. The relative difference ΔSUV between cPET and dPET was calculated for each SUV-parameter. Furthermore, we calculated repeatability coefficients, reflecting the 95% confidence interval of ΔSUV.
RESULTS: We included 128 lesions with an average size of 19 ± 14 mm. Average ΔSUVs were 6-8% with dPET values being higher for all three SUV-parameters (p < 0.001). ΔSUVmax was significantly higher than ΔSUVmean (8% vs. 6%, p = 0.002) and than ΔSUVpeak (8% vs. 7%, p = 0.03). Repeatability coefficients across individual lesions were 27% (ΔSUVmean and ΔSUVpeak) and 33% (ΔSUVmax) (p < 0.001).
CONCLUSIONS: With EARL-accredited conventional and digital PET, we found a limited SUV variability with average differences up to 8%. Furthermore, only a limited number of lesions showed a SUV difference of more than 30%. These findings indicate that EARL standardisation works. TRIAL REGISTRATION: This prospective study was registered on the 31th of October 2017 at ClinicalTrials.cov. URL: https://clinicaltrials.gov/ct2/show/NCT03457506?id=03457506&rank=1.

Entities:  

Keywords:  Cancer; Conventional PET; Digital PET; EARL-accreditation; FDG-PET

Year:  2019        PMID: 31823097     DOI: 10.1186/s13550-019-0569-7

Source DB:  PubMed          Journal:  EJNMMI Res            Impact factor:   3.138


  6 in total

1.  Pretreatment 18F-FDG PET/CT-Derived Parameters in Predicting Clinical Outcomes of Locally Advanced Upper Third Esophageal Squamous Cell Carcinoma After Definitive Chemoradiation Therapy.

Authors:  Le Ngoc Ha; Nguyen Dinh Chau; Bui Quang Bieu; Mai Hong Son
Journal:  Nucl Med Mol Imaging       Date:  2022-05-10

2.  Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.

Authors:  Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu
Journal:  J Nucl Cardiol       Date:  2022-07-21       Impact factor: 3.872

3.  Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT.

Authors:  Ian Alberts; Christos Sachpekidis; George Prenosil; Marco Viscione; Karl Peter Bohn; Clemens Mingels; Kuangyu Shi; Ali Ashar-Oromieh; Axel Rominger
Journal:  Ann Nucl Med       Date:  2021-02-07       Impact factor: 2.668

4.  EARL compliance measurements on the biograph vision Quadra PET/CT system with a long axial field of view.

Authors:  George A Prenosil; Michael Hentschel; Thilo Weitzel; Hasan Sari; Kuangyu Shi; Ali Afshar-Oromieh; Axel Rominger
Journal:  EJNMMI Phys       Date:  2022-04-08

5.  Synthetic MRI for Radiotherapy Planning for Brain and Prostate Cancers: Phantom Validation and Patient Evaluation.

Authors:  Pierrick Gouel; Sebastien Hapdey; Arthur Dumouchel; Isabelle Gardin; Eva Torfeh; Pauline Hinault; Pierre Vera; Sebastien Thureau; David Gensanne
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

6.  The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.

Authors:  Ian Alberts; Jan-Niklas Hünermund; Christos Sachpekidis; Clemens Mingels; Viktor Fech; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur Radiol       Date:  2021-04-15       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.